
AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own DRDGOLD today, you need to believe in its ability to keep turning tailings retreatment into solid cash generation, while managing South African operating realities and a changing gold price backdrop. The FTSE All-World inclusion mostly affects the shareholder base rather than the underlying business, but it can still amplify short term catalysts by bringing in more index-linked and benchmark-aware flows after a sharp 30-day pullback. That extra liquidity may reduce trading volatility around production updates, dividend decisions and the CFO transition, yet it does not remove key risks such as weather disruptions, cost pressure against its R995,000/kg guidance and an unstable dividend record. In other words, the index news could reshape who owns DRDGOLD, not what the core risks are.
However, concentration in one commodity and one country adds a layer investors should understand. DRDGOLD's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.Explore 4 other fair value estimates on DRDGOLD - why the stock might be worth less than half the current price!
Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com